Mutual of America Capital Management LLC Invests $2.34 Million in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Mutual of America Capital Management LLC purchased a new position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 64,214 shares of the company's stock, valued at approximately $2,344,000. Mutual of America Capital Management LLC owned approximately 0.10% of SpringWorks Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the company. Teacher Retirement System of Texas raised its holdings in shares of SpringWorks Therapeutics by 4.7% in the 3rd quarter. Teacher Retirement System of Texas now owns 9,770 shares of the company's stock worth $226,000 after acquiring an additional 441 shares during the last quarter. Royal Bank of Canada boosted its stake in shares of SpringWorks Therapeutics by 1.8% in the 1st quarter. Royal Bank of Canada now owns 26,465 shares of the company's stock worth $1,494,000 after buying an additional 479 shares during the last quarter. Sei Investments Co. grew its holdings in shares of SpringWorks Therapeutics by 4.0% in the second quarter. Sei Investments Co. now owns 14,198 shares of the company's stock valued at $372,000 after acquiring an additional 549 shares in the last quarter. American International Group Inc. increased its position in shares of SpringWorks Therapeutics by 3.4% during the fourth quarter. American International Group Inc. now owns 17,036 shares of the company's stock valued at $443,000 after acquiring an additional 553 shares during the last quarter. Finally, Envestnet Asset Management Inc. boosted its position in SpringWorks Therapeutics by 4.0% in the third quarter. Envestnet Asset Management Inc. now owns 14,401 shares of the company's stock worth $411,000 after purchasing an additional 558 shares during the last quarter.

Insider Buying and Selling

In other SpringWorks Therapeutics news, insider Daniel Pichl sold 15,000 shares of the company's stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $50.10, for a total transaction of $751,500.00. Following the completion of the transaction, the insider now owns 45,212 shares of the company's stock, valued at approximately $2,265,121.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 7.61% of the stock is owned by insiders.

SpringWorks Therapeutics Trading Down 5.6 %

Shares of NASDAQ SWTX traded down $2.37 during mid-day trading on Friday, hitting $40.10. The company had a trading volume of 1,413,521 shares, compared to its average volume of 649,930. SpringWorks Therapeutics, Inc. has a 1 year low of $18.00 and a 1 year high of $53.92. The stock's 50-day moving average price is $47.96 and its 200-day moving average price is $37.16. The company has a market capitalization of $2.96 billion, a price-to-earnings ratio of -7.80 and a beta of 0.83.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($1.24) by ($0.20). The company had revenue of $5.45 million for the quarter, compared to the consensus estimate of $1.26 million. During the same quarter last year, the business posted ($1.19) EPS. As a group, equities research analysts forecast that SpringWorks Therapeutics, Inc. will post -4.71 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on SWTX. Wedbush lifted their target price on SpringWorks Therapeutics from $60.00 to $70.00 and gave the stock an "outperform" rating in a research note on Monday, February 26th. Guggenheim initiated coverage on shares of SpringWorks Therapeutics in a research report on Monday, February 5th. They issued a "buy" rating and a $75.00 price objective on the stock. JPMorgan Chase & Co. increased their target price on shares of SpringWorks Therapeutics from $73.00 to $74.00 and gave the company an "overweight" rating in a research report on Wednesday, March 6th. HC Wainwright lifted their price target on shares of SpringWorks Therapeutics from $73.00 to $74.00 and gave the stock a "buy" rating in a report on Wednesday, March 6th. Finally, Barclays increased their price objective on SpringWorks Therapeutics from $47.00 to $63.00 and gave the company an "overweight" rating in a report on Thursday, February 29th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $68.00.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.